Kolotkin RL, et al. - This study was performed to investigate the improvements in health-related quality of life (HRQoL) over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity. Compared with placebo, liraglutide 3.0 mg, plus diet and exercise, was correlated with long-term improvements in HRQoL with obesity or overweight with comorbidity.